BIIB•benzinga•
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Summary
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga